CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG
…, O Yockey, M Xu, A Mendoza, ER Hernandez… - Nature …, 2020 - nature.com
Embryonal rhabdomyosarcoma (ERMS) is a childhood cancer that expresses myogenic
master regulatory factor MYOD but fails to differentiate. Here, we show that the zinc finger …
master regulatory factor MYOD but fails to differentiate. Here, we show that the zinc finger …
Rigosertib induces mitotic arrest and apoptosis in RAS-mutated rhabdomyosarcoma and neuroblastoma
JT Kowalczyk, X Wan, ER Hernandez, R Luo… - Molecular cancer …, 2021 - AACR
Relapsed pediatric rhabdomyosarcomas (RMS) and neuroblastomas (NBs) have a poor
prognosis despite multimodality therapy. In addition, the current standard of care for these …
prognosis despite multimodality therapy. In addition, the current standard of care for these …
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
S Stauffer, JS Roth, ER Hernandez, JT Kowalczyk… - Cancers, 2024 - mdpi.com
Simple Summary The prognosis for patients with relapsed neuroblastoma is poor, and novel
treatment options for these patients are needed. Some relapsed neuroblastoma tumors …
treatment options for these patients are needed. Some relapsed neuroblastoma tumors …
[HTML][HTML] Postoperative virtual reality for recovery after bariatric surgery: study protocol for a randomised clinical trial
…, M Joseph, T Sadhwani, N Beydoun, ER Hernandez… - BJA open, 2024 - Elsevier
Background Enhanced Recovery After Surgery (ERAS) protocols for bariatric surgery
improve clinical outcomes. However, the impact of ERAS protocols on patient satisfaction is …
improve clinical outcomes. However, the impact of ERAS protocols on patient satisfaction is …
Intraoperative virtual reality for older patients undergoing total knee arthroplasty: study protocol for a randomized clinical trial
…, M Joseph, T Sadhwani, N Beydoun, ER Hernandez… - 2024 - researchsquare.com
Background: In an aging surgical patient population, preventing complications such as
oversedation has taken increasing priority in perioperative care. Intraoperative use of Virtual …
oversedation has taken increasing priority in perioperative care. Intraoperative use of Virtual …
The RASopathies: from pathogenetics to therapeutics
KE Hebron, ER Hernandez… - Disease models & …, 2022 - journals.biologists.com
The RASopathies are a group of disorders caused by a germline mutation in one of the
genes encoding a component of the RAS/MAPK pathway. These disorders, including …
genes encoding a component of the RAS/MAPK pathway. These disorders, including …
Advancing RAS/RASopathy therapies: an NCI‐sponsored intramural and extramural collaboration for the study of RASopathies
…, D Esposito, ER Hernandez… - American Journal of …, 2020 - Wiley Online Library
RASopathies caused by germline pathogenic variants in genes that encode RAS pathway
proteins. These disorders include neurofibromatosis type 1 (NF1), Noonan syndrome (NS), …
proteins. These disorders include neurofibromatosis type 1 (NF1), Noonan syndrome (NS), …
Epigenetic manipulation can sensitize AML cells to differentiate with ATRA
K Heimdal, B Ghimire, ER Hernandez, HJG Super - Cancer Research, 2019 - AACR
Human acute myeloid leukemia (AML), the most common type of acute leukemia, has
approximately eight subtypes, many of which have poor prognosis. Most of these subtypes are …
approximately eight subtypes, many of which have poor prognosis. Most of these subtypes are …
Abstract B038: Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer
…, A Baker, A Perciaccante, ER Hernandez… - Molecular Cancer …, 2023 - AACR
Directly targeting RAS is a desirable approach for treating RAS-mutated tumors because direct
RAS inhibitors block all RAS effector pathways simultaneously. Recently, several groups …
RAS inhibitors block all RAS effector pathways simultaneously. Recently, several groups …
Acknowledgment to the Reviewers of Electronics in 2022
ABMM Rahman, A Zekry, AKMZ Hossain, A Ibrahim… - 2023 - search.ebscohost.com
Thanks to the efforts of our reviewers in 2022, the median time to first decision was 15 days
and the median time to publication was 36 days. I Electronics i was able to uphold its high …
and the median time to publication was 36 days. I Electronics i was able to uphold its high …